Actelion ups guidance after first-quarter earnings beat views

April 21, 2015 5:14 AM

14 0

ZURICH, April 21 (Reuters) - Actelion, Europe's biggest biotech firm, on Tuesday upped its full-year guidance after reporting first-quarter earnings that exceeded analysts' estimates.

The Swiss drugs company reported a 10 percent year-on-year rise in first-quarter product sales to 515 million Swiss francs ($538.42 million), generating net income of 159 million francs, up 25 percent on the same period last year.

Also read: Carl Icahn buys stake in software provider VMware: CNBC

Read more

To category page